252 related articles for article (PubMed ID: 12184062)
1. The clinical profile of the angiotensin II receptor blocker eprosartan.
Hedner T
J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
[TBL] [Abstract][Full Text] [Related]
2. Management of hypertension: the advent of a new angiotensin II receptor antagonist.
Hedner T
J Hypertens Suppl; 1999 Jun; 17(2):S21-5. PubMed ID: 10465063
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
Brooks DP; Ruffolo RR
J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
[TBL] [Abstract][Full Text] [Related]
4. Eprosartan for the treatment of hypertension.
Ruilope L; Jäger B
Expert Opin Pharmacother; 2003 Jan; 4(1):107-14. PubMed ID: 12517247
[TBL] [Abstract][Full Text] [Related]
5. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B
Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
[TBL] [Abstract][Full Text] [Related]
6. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
de la Sierra A; Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin blockade with eprosartan: vascular and functional implications.
Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
[TBL] [Abstract][Full Text] [Related]
8. AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.
Heusser K; Vitkovsky J; Schmieder RE; Schobel HP
Auton Neurosci; 2003 Aug; 107(1):45-51. PubMed ID: 12927226
[TBL] [Abstract][Full Text] [Related]
9. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
Rupp H
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S25-9. PubMed ID: 18093411
[TBL] [Abstract][Full Text] [Related]
10. Clinical profile of eprosartan.
Puig JG; López MA; Bueso TS; Bernardino JI; Jiménez RT;
Cardiovasc Drugs Ther; 2002 Dec; 16(6):543-9. PubMed ID: 12766389
[TBL] [Abstract][Full Text] [Related]
11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
12. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
Aulakh GK; Sodhi RK; Singh M
Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
Johnston CI
Blood Press Suppl; 2000; 1():9-13. PubMed ID: 11059629
[TBL] [Abstract][Full Text] [Related]
14. AT1 blockers and uric acid metabolism: are there relevant differences?
Puig JG; Torres R; Ruilope LM
J Hypertens Suppl; 2002 Jun; 20(5):S29-31. PubMed ID: 12184060
[TBL] [Abstract][Full Text] [Related]
15. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
[TBL] [Abstract][Full Text] [Related]
16. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
17. Comparative antihypertensive effects of angiotensin II receptor antagonists.
Burnier M; Brunner HR
J Am Soc Nephrol; 1999 Apr; 10 Suppl 12():S278-82. PubMed ID: 10201883
[TBL] [Abstract][Full Text] [Related]
18. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Ram CV; Rudmann MA
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II antagonists: a new class of antihypertensive agent.
Waeber B; Brunner HR
Br J Clin Pract; 1996; 50(5):265-8. PubMed ID: 8794603
[TBL] [Abstract][Full Text] [Related]
20. [Prospects for pharmacological effects on renin-angiotensin and sympathetic nervous systems in patients with arterial hypertension].
Chikhladze NM
Ter Arkh; 2000; 72(12):67-9. PubMed ID: 11201840
[No Abstract] [Full Text] [Related]
[Next] [New Search]